Therapeutic thrombocytapheresis in myeloproliferative neoplasms: A single-institution experience

被引：7

作者：

Nguyen, Thanh Ha ^{[1
]}

Bach, Khanh Quoc ^{[1
]}

Vu, Hung Quang ^{[1
]}

Nguyen, Nhat Quoc ^{[1
]}

Duong, Thien Doan ^{[1
]}

Wheeler, Jennifer ^{[2
]}

机构：

[1] Natl Inst Hematol & Blood Transfus, Hanoi, Vietnam

[2] Terumo BCT, Lakewood, CO USA

来源：

JOURNAL OF CLINICAL APHERESIS | 2021年 / 36卷 / 01期

关键词：

chronic myeloid leukemia; essential thrombocythemia; thrombocytapheresis; VON-WILLEBRAND-DISEASE; SYMPTOMATIC THROMBOCYTOSIS; COAGULATION PARAMETERS; WRITING COMMITTEE; ADVERSE-REACTIONS; AMERICAN SOCIETY; PLATELETPHERESIS; APHERESIS; BLOOD; MANAGEMENT;

D O I：

10.1002/jca.21847

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Thrombocytosis is usually seen in myeloproliferative neoplasms (MPNs) and associated with thrombohemorrhagic complications. Therapeutic thrombocytapheresis using an automatic cell separator can help to achieve prompt platelet count reduction to decrease the rate of thrombotic events. In this study, we report a single center's experience in managing MPN patients with thrombocytapheresis prior to chemotherapy. Thrombocytapheresis procedures were performed in 185 MPN patients with thrombocytosis between January 2016 and June 2017. The median percentage reduction of platelets was 44.5% and the median percentage removal efficiency was 65.2% for 83 procedures where the waste bag was sampled. Procedures were generally well tolerated with few patients having mild adverse events (13 out of 185 patients).

引用

页码：101 / 108

页数：8

共 39 条

[1]

Amanat ST, 2015, JCPSP-J COLL PHYSICI, V25, P403, DOI 06.2015/JCPSP.403406

[2]

BARON BW, 1993, CANCER-AM CANCER SOC, V72, P1209, DOI 10.1002/1097-0142(19930815)72:4<1209::AID-CNCR2820720413>3.0.CO

[3]

2-4

[4] The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review [J].